Literature DB >> 17488707

Therapeutic potential of arsenic trioxide with or without interferon-alpha for relapsed/refractory adult T-cell leukemia/lymphoma.

Kenji Ishitsuka, Junji Suzumiya, Mikiko Aoki, Kentaro Ogata, Shuuji Hara, Kazuo Tamura.   

Abstract

Arsenic trioxide (As2O3) with or without interferon-a (IFN) was given to 4 patients with relapsed/refractory adult T-cell leukemia/lymphoma (ATLL). Treatment with As2O3 and IFN showed an encouraging response in two moderately-aggressive ATLL patients, while As2O3 alone was ineffective in two patients with very aggressive and rapidly progressing ATLL. Further studies are needed to clarify the role of As2O3 and its usefulness when combined with IFN for the treatment of ATLL.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17488707     DOI： 10.3324/haematol.10703

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  6 in total

Review 1.  Arsenic trioxide - An old drug rediscovered.

Authors:  Ashkan Emadi; Steven D Gore
Journal:  Blood Rev       Date:  2010-05-15       Impact factor: 8.250

2.  Complete remission of a relapsing adult T cell leukaemia following treatment of a secondary acute promyelocytic leukaemia: towards a reappraisal of arsenic trioxide and all-transretinoic acid?

Authors:  Marie-Olivia Chandesris; David Ghez; Caroline Besson; Felipe Suarez; Richard Delarue; Marie-Thérèse Rubio; Ali Bazarbachi; Bruno Varet; Olivier Hermine
Journal:  BMJ Case Rep       Date:  2009-08-10

3.  Arsenic induced complete remission in a refractory T-ALL patient with a distinct T-cell clonal evolution without molecular complete remission: A case report.

Authors:  Suijing Wu; Ling Xu; Xin Huang; Suxia Geng; Yan Xu; Shaohua Chen; Lijian Yang; Xiuli Wu; Janyu Weng; Xin DU; Yangqiu Li
Journal:  Oncol Lett       Date:  2016-05-05       Impact factor: 2.967

4.  Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia.

Authors:  Hiba El Hajj; Marwan El-Sabban; Hideki Hasegawa; Ghazi Zaatari; Julien Ablain; Shahrazad T Saab; Anne Janin; Rami Mahfouz; Rihab Nasr; Youmna Kfoury; Christophe Nicot; Olivier Hermine; William Hall; Hugues de Thé; Ali Bazarbachi
Journal:  J Exp Med       Date:  2010-12-06       Impact factor: 14.307

Review 5.  Controversies in targeted therapy of adult T cell leukemia/lymphoma: ON target or OFF target effects?

Authors:  Rihab Nasr; Hiba El Hajj; Youmna Kfoury; Hugues de Thé; Olivier Hermine; Ali Bazarbachi
Journal:  Viruses       Date:  2011-06-14       Impact factor: 5.048

Review 6.  Adult T Cell Leukemia-Lymphoma (ATL): State of the Art.

Authors:  Adrienne A Phillips; Janine C K Harewood
Journal:  Curr Hematol Malig Rep       Date:  2018-08       Impact factor: 4.213
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.